Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03180502 · ClinicalTrials.gov registry record · Phase 2
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
A Phase 2 study of Glioma and Anaplastic Astrocytoma, sponsored by NRG Oncology.
- Active
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 20
- Study locations
NCT03180502 is a Phase 2 study of Glioma and Anaplastic Astrocytoma that is active but no longer recruiting, run by NRG Oncology. The registered enrollment target is 120 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03180502, a Phase 2 study of Glioma and Anaplastic Astrocytoma, is active but no longer recruiting, sponsored by NRG Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation directly to the tumor and may cause less damage to normal tissue. Intensity-modulated or photon beam radiation therapy uses high-energy x-ray beams shaped to treat the tumor and may also cause less damage to normal tissue. It is not yet known if proton beam radiation therapy is more effective than photon-based beam intensity-modulated radiation therapy in treating patients with glioma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Laboratory Biomarker Analysis
- RADIATION Intensity-Modulated Radiation Therapy
- RADIATION Proton Beam Radiation Therapy
Study Locations (20)
Maryland
- Maryland Proton Treatment Center - Baltimore
- University of Maryland/Greenebaum Cancer Center - Baltimore
- UM Upper Chesapeake Medical Center - Bel Air
- Central Maryland Radiation Oncology in Howard County - Columbia
- UM Baltimore Washington Medical Center/Tate Cancer Center - Glen Burnie
Georgia
- Emory Proton Therapy Center - Atlanta
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
Illinois
- Northwestern University - Chicago
- Northwestern Medicine Cancer Center Delnor - Geneva
- Northwestern Medicine Cancer Center Warrenville - Warrenville
Kansas
- University of Kansas Cancer Center - Kansas City
- University of Kansas Cancer Center-Overland Park - Overland Park
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Florida
- Boca Raton Regional Hospital - Boca Raton
- Miami Cancer Institute - Miami
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
Maine
- MaineHealth Maine Medical Center- Scarborough - Scarborough
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-01-23 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03180502
The ClinicalTrials.gov registry entry for NCT03180502 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (43% lower). The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Glioma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT03180502 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Maryland, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT03180502 about?
NCT03180502 is a clinical study titled "Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma". This randomized phase II clinical trial studies the side effects and how well proton beam or intensity-modulated radiation therapy works in preserving brain function in patients with IDH mutant grade II or III glioma. Proton beam radiation therapy uses tiny charged particles to deliver radiation dir...
What is the current status of trial NCT03180502?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2018-01-23. Estimated completion is 2027-06-01.
What conditions does trial NCT03180502 study?
This clinical trial studies the following conditions: Glioma, Anaplastic Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma, WHO Grade 3 Glioma.
What interventions are being tested in trial NCT03180502?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Intensity-Modulated Radiation Therapy (RADIATION), Proton Beam Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03180502?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03180502 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.